Compare WHLRD & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHLRD | GALT |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | 56 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 232.3M |
| IPO Year | N/A | N/A |
| Metric | WHLRD | GALT |
|---|---|---|
| Price | $37.97 | $4.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | N/A | ★ 714.1K |
| Earning Date | N/A | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $0.73 |
| 52 Week High | N/A | $7.13 |
| Indicator | WHLRD | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 36.24 |
| Support Level | $37.18 | $6.03 |
| Resistance Level | $38.87 | $7.13 |
| Average True Range (ATR) | 1.31 | 0.71 |
| MACD | 0.22 | -0.09 |
| Stochastic Oscillator | 49.24 | 17.12 |
Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Winslow Plaza in Sicklerville, New Jersey and many more.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.